FDA: Ignore the false racial equity argument for keeping Makena
A pharma company is arguing that Makena should be kept on the market because it may work in Black people. But it doesn't work in any people.
Martha Nolan Covis Pharma Human Development Drug Administration Bristol Myers Squibb Us National Institute Of Child Health
Source: statnews.com